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but the position of the urethra was seen on some MRI slices and 
extrapolated on others. Prophylactic alpha-blockers were not given.  
Results: Six patients experienced urinary symptoms resulting in an 
IPSS rise of 14 points or more. Maximal IPSS scores during the follow-
up period ranged from 4-35. Mean DVH parameters are shown in the 
table below.  
 
  
A significant correlation was found between the volume of urethra 
receiving 40 Gy (P=0.011) and 42 Gy (P=0.0006) and the maximum IPSS 
after prostate SBRT. This association remains highly significant 
(P=0.002) even when adjusted for the baseline IPSS. Patients with a 
V42 Gy below the mean value (47%) rarely experienced toxicity (2/11 
patients) compared with a V42 Gy>47% where 4/7 had a significant 
IPSS rise. The dose to 10% of the bladder was also correlated with 
maximal IPSS score (P=0.039).  Volume of urethra receiving 45.6 Gy 
was often 0% and was not correlated with IPSS. For the other bladder 
parameters tested (D40%, dose to hottest 10cc and 3cc) no significant 
correlation was observed in this series. Bladder and prostate volume 
did not predict for symptoms and neither did the IPSS score at 
baseline.  
Conclusions: Prediction of those who will experience acute GU 
symptoms after prostate SBRT is difficult but appears highly 
correlated with dose to the urethra. We suggest that keeping the 
urethral V42Gy <47% may reduce acute urinary morbidity or where this 
is not possible, the utility of prophylactic alpha-blockers could be 
examined.  
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Purpose/Objective: To quantify inter-/intrafraction prostate motion 
and patient setup variation by using kV cone beam CT (CBCT) scans 
during the course of prostate RapidArc therapy.  
Materials and Methods: 1288 weekly CBCT scans were obtained on 
161 patients with prostate cancer [MRI stages:T1-2%, T2-22%, T3a-
11%, T3b 65%] undergoing high- dose RapidArc therapy (mean total 
dose: 81.1Gy). Additionally, 528 weekly post-treatment CBCT scans of 
66 of these patients were acquired. The CBCT scans were 
superimposed on the Planning-CT scans by using the Eclipse automatic 
registration and match algorithm of the EclipseTM planning module 
version (VARIS Vision 8.6.07). Inter-/intrafraction motion defined by 
CBCT consists of two components: the prostate movement and the 
patient setup displacement. Deviations were measured in 
anteroposterior (AP), right- left (RL), and superior- inferior (SI) 
directions, as well as rotation angles around the AP axis relative to 
the isocenter. 
Results: The interfraction motion was most significant in AP direction, 
followed by SI and RL directions. The mean prostate deviation (mean± 
SD) was 1.7mm ± 1.5mm (max.:15 mm), 1.5mm ± 1.4mm (max.: 
11mm) and 0.9mm ± 0.8 mm (max.: 7mm) in the AP and SI and RL 
directions, respectively. The mean interfraction rotation was 
0.8°±0.6°(max.:4.7°) around the AP axis. The intrafraction motion 
was significantly smaller; the mean intrafraction displacements were 
0.8mm ± 0.7 mm (max.: 6 mm), 0.7mm ± 0.6mm (max.:4 mm), and 
0.9mm ± 0.7mm (max.:6 mm) in AP, SI and RL directions, 
respectively. The mean intrafraction rotation was 0.5°±0.5° 
(max.:4.7°) around the AP axis. The frequency of interfraction motion 
was more than 4mm in 5.2%, 5%, 0.7% and more than 5mm in 2.3%, 
2.3%, 0.2% of patients in AP, SI and RL directions, respectively. An 
intrafraction displacement of more than 2mm occurred in 3.5%, 1.2%, 
4.2% and more than 3mm in 0.8%,0.2%, 1.5% of measurements in AP, 
SI and RL directions, respectively. The frequency of inter-
/intrafraction rotation was >2° in 11.6% / 4.2%, > 2.5° in 6.8% / 3% 
and > 3° in 2.7% / 1.7% of patients, respectively. 
Conclusions: Our findings suggest that the interfraction motion was 
small and occurred predominantly in AP direction. In contrast, the 
intrafraction variability seems to be clinically insignificant. The use of 
cone-beam-CT guided RapidArc allows both an accurate prostate 
localization and shorter treatment times for dose-escalated 
irradiation, thus enabling significant margin reduction.  
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Purpose/Objective: With the development of real time tracking 
technologies we have the capabilities to conform radiotherapy 
directly to the target before (inter-fraction) and during (intra-
fraction) treatment delivery providing accurate and effective 
targeting , allowing us to respond and adapt accordingly. The Calypso 
™ tracking system is used to localise and track the prostate. This 
system has been clinical at the proposed site since January 2010 and 
to date has effectively treated more than 30 patients. 
Materials and Methods: Calypso ™ is a motion management system 
that involves inserting 3 Beacon electromagnetic transponders into the 
prostate. The systems array excites these transponders causing them 
to emit radiofrequency signals, it receives and uses these signals to 
map their exact location. This information gets sent to the tracking 
station which verifies treatment isocentre and tracks the movement 
of the transponders during treatment delivery. To improve treatment 
delivery we conducted a study to determine new planning target 
volume margins for prostate patients' implanted with fiducial markers 
and those implanted with electromagnetic transponders. We used the 
Calypso™ data from the first 20 prostate patients who we localised 
using 3 skin marker tattoos followed by transponder detection and 
auto couch repositioning. Intra-fraction organ motion was monitored 
continuously using the Calypso™ system recording sub-millimetre 
motion throughout. 
Results: A total of 740 fractions were analysed and recommendations 
for new margins calculated using van Herks formula. The margins for 
fiducial marker patients are predictably greater than those of the 
transponder tracking, this takes into account we are unable to correct 
for intra-fraction motion on the fiducial group. The margin values are 
currently being verified by an independent statistician to ensure 
accuracy of calculation, formula use and the recommended 
guidelines. 
Conclusions: Localisation and intra-fraction tracking with Calypso™ 
and fiducial localisation allows a marked reduction in PTV margins. 
Although fiducial localisation margins cannot be as tight due to the 
intra-fractional prostate motion being a limiting factor. Applying 
these new margins will undoubtedly reduce normal tissue toxicity and 
side effects commonly …..by this group of patients. 
Limitations: The transponders cause voids on MRI follow up scans, 
tracking system cannot be used in conjunction with artificial hips 
/metal prosthesis around the pelvic area. 
Future: Once the new margins are implemented outcomes data will 
be collected. Aim to utilise the Calypso tracking™ system on other 
areas of the body. Study proposal in the use of transponders in the 
pancreas in line with University Hospital of Pennsylvania 13 
   
 
 
 
 
 
  
  
  
  
 
